01 October 2019
Visiongain has launched a new pharma report: Pharma Wholesale Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.
The pharmaceutical wholesale and distribution market is influenced by the play of a variety of factors; it has both strengths and weaknesses and faces both opportunities and threats. The market will be driven by an overall increased demand for pharmaceuticals owing to the growing ageing population of developed countries and the increasing access to healthcare of the expanding middle class in the emerging economies.
The lead analyst of the report commented "Over the course of the forecast period, all national pharmaceutical wholesale and distribution markets discussed in this report will experience growth. However, this growth will be significantly faster in emerging markets, such as China. Growth will be faster in these emerging markets as it mirrors growth in the pharmaceutical markets; demand for prescription pharmaceuticals will become much higher in developing countries."
Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Cardinal Health, McKesson, Medipal, PHOENIX Group, Shanghai Pharma, SINOPHARM, Suzuken, Walgreens Boots Alliance and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
4D printing technology finds an abundant scope of use in the medical industry and has brought in a significant revolution in the healthcare industry.
09 March 2021
Rising incidence and prevalence of cardiovascular diseases, osteoarthritis disorder, and multiple cancer are expected to be major driving factors for the growth of the 3D Cell Culture market during the forecast period.
09 March 2021
In recent years, there are major technological innovations that have taken place in the 3D bioprinting industry for numerous medical applications, including cancer drugs, bone and cartilage development, skin tissue development, and liver modeling.
09 March 2021
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.